Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?

Author： Mueller Lisa L   Taketsuma Costa Silvia Moreira  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.24, Iss.1, 2014-01, pp. : 1-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Compulsory pharmaceutical patent licensing in Brazil: the controversy of public interest

By Rodrigues da Silva Caio   Galvão de Botton Leonor  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 6, 2013-11 ,pp. : 685-687

Future Science

Access to resources Recommend Favorite

Anvisa, Brazil's regulatory body, has announced the lowest drug price increases

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Pharmaceutical patent litigation in Europe

By Cook T.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 2, 1999-02 ,pp. : 181-187

Informa Healthcare

Access to resources Recommend Favorite

Developing trends in pharmaceutical patent claims

By Cook T.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 5, 1999-05 ,pp. : 635-643

Informa Healthcare

Access to resources Recommend Favorite

Probiotics: potential pharmaceutical applications

By Kaur I.P.   Chopra K.   Saini A.  

European Journal of Pharmaceutical Sciences, Vol. 15, Iss. 1, 2002-02 ,pp. : 1-9

Elsevier

Access to resources Recommend Favorite